Publication | Open Access

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

Japanese PatientsOncologyMalignant DiseaseMedicinePathologyPharmacokinetic TrialCancer TreatmentPharmacologyRadiation OncologyCancer ResearchSolid Malignant Tumors